Oncology trials indexed live. Bioregulator studies registered and operating.

ClinicalTrials.gov v2 API supplies oncology trial data on every match request. The 27 Atumnus-registered observational studies are filed under FDAAA 801, IRB-approved.

Oncology trials

Urologic malignancies — currently recruiting

NCT numbers available to credentialed physicians

Indication	Trial	Biomarker requirement	Phase	Status
mCRPC	Prostate — AR pathway inhibitor combination	AR-V7, BRCA1/2	Phase II	Recruiting
Urothelial carcinoma	Bladder — FGFR3 targeted therapy	FGFR3 alteration	Phase II	Recruiting
Clear cell RCC	RCC — HIF-2α inhibitor expansion	VHL mutation	Phase II	Recruiting
BRCA1/2 mCRPC	Prostate — PARP inhibitor + checkpoint	HRR gene panel	Phase I/II	Recruiting
MIBC	Bladder — neoadjuvant combination	FGFR3, TP53	Phase II	Recruiting
Advanced RCC	RCC — dual checkpoint blockade	PD-L1, PBRM1	Phase III	Recruiting

Showing representative urologic oncology trials. Full index available to credentialed physicians and lab partners. Full index available to credentialed physicians and lab partners.

Matching architecture

Four-component pipeline. Patient summary to ranked trial list in under one second.

Ranking model

TrialSpace

Patient clinical summaries and trial target populations embedded in shared vector space. Narrows the full ClinicalTrials.gov oncology index to a ranked candidate set per patient summary.

Classification model

TrialChecker

Binary patient-trial eligibility classification. Criterion by criterion — age range, mutation status, prior therapy lines, organ function thresholds. Peer-reviewed criterion classification. Validated against published eligibility criteria.

Data source

ClinicalTrials.gov v2 API

All trial data pulled live on every match request. No internal database. Trial updates and closure reflected immediately.

Privacy

On-operator inference

Models run inside operator network. No PHI transmitted. Trained on synthetic EHR data. No BAA with any model vendor required.

Bioregulator studies

27 registered observational studies. IRB-approved. Enrollment open.

Atumnus LLC. ClinicalTrials.gov. FDAAA 801. Each study covers a peptide bioregulator compound with characterized mechanism in peer-reviewed literature.

Compound	Studies	Enrollment	Indication	Mechanism (literature-grounded)
BPC-157	4	Open	Musculoskeletal regeneration, gut mucosa repair	GH receptor modulation, NO pathway, angiogenesis
MOTS-c	3	Open	Metabolic function, mitochondrial health	AMPK activation, mitochondrial biogenesis
Epithalon	4	Open	Telomere biology, circadian regulation	Telomerase activation, melatonin pathway
Semax	3	Open	Neuroprotection, cognitive function	BDNF/NGF upregulation, dopaminergic modulation
KPV	3	Open	Inflammation, mucosal repair	MC1R agonism, NF-κB suppression
Additional compounds	10	Open	See registry for full compound list	Various — filed per protocol

Study index access

NCT numbers, eligibility criteria, and enrollment documentation are available to credentialed physicians and lab partners. Sponsor inquiries include indication, phase, and enrollment target.

Physician credentialing Lab partnership Sponsor inquiry